Alnylam Pharmaceuticals (ALNY) EPS (Weighted Average and Diluted) (2019 - 2026)
Alnylam Pharmaceuticals posted quarterly EPS (Weighted Average and Diluted) of $1.51 for Q1 2026, up 1178.57% year-on-year from $0.12 in Q1 2025, and up 84.15% on a QoQ basis from $0.82 in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 8 years of EPS (Weighted Average and Diluted) data on file, last reported at $1.51 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 1178.57% year-over-year to $1.51; the trailing twelve-month figure through Mar 2026 stood at $3.66 (up 304.47% YoY), and the FY2025 full-year result was $2.33, up 206.88% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $1.51, up from $0.82 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $1.84 in Q3 2025 and bottomed at -$3.32 in Q3 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.65 (2024), against an average of -$0.68.
- The widest annual swing landed in 2025, when EPS (Weighted Average and Diluted) sank 292.31%; it then jumped 1178.57% in 2026.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.68 in 2022, then jumped by 35.12% to -$1.09 in 2023, then surged by 40.37% to -$0.65 in 2024, then soared by 226.15% to $0.82 in 2025, then soared by 84.15% to $1.51 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $1.51 (Q1 2026), $0.82 (Q4 2025), and $1.84 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -2.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.51 |
| Dec 31, 2025 | 0.82 |
| Sep 30, 2025 | 1.84 |
| Jun 30, 2025 | -0.51 |
| Mar 31, 2025 | -0.14 |
| Dec 31, 2024 | -0.65 |
| Sep 30, 2024 | -0.87 |
| Jun 30, 2024 | -0.13 |
| Mar 31, 2024 | -0.52 |
| Dec 31, 2023 | -1.09 |
| Sep 30, 2023 | 1.15 |
| Jun 30, 2023 | -2.21 |
| Mar 31, 2023 | -1.40 |
| Dec 31, 2022 | -1.68 |
| Sep 30, 2022 | -3.32 |
| Jun 30, 2022 | -2.29 |
| Mar 31, 2022 | -2.00 |
| Dec 31, 2021 | -2.16 |
| Sep 30, 2021 | -1.72 |
| Jun 30, 2021 | -1.61 |
| Mar 31, 2021 | -1.71 |
| Dec 31, 2020 | -2.09 |
| Sep 30, 2020 | -2.18 |
| Jun 30, 2020 | -1.56 |
| Dec 31, 2019 | -2.53 |